KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vertex Pharmaceuticals (VRTX) Long-Term Investments (2016 - 2025)

Historic Long-Term Investments for Vertex Pharmaceuticals (VRTX) over the last 6 years, with Q3 2025 value amounting to $5.7 billion.

  • Vertex Pharmaceuticals' Long-Term Investments rose 2167.11% to $5.7 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $5.7 billion, marking a year-over-year increase of 2167.11%. This contributed to the annual value of $5.1 billion for FY2024, which is 10449.6% up from last year.
  • Vertex Pharmaceuticals' Long-Term Investments amounted to $5.7 billion in Q3 2025, which was up 2167.11% from $5.6 billion recorded in Q2 2025.
  • In the past 5 years, Vertex Pharmaceuticals' Long-Term Investments ranged from a high of $5.7 billion in Q3 2025 and a low of $112.2 million during Q4 2022
  • For the 4-year period, Vertex Pharmaceuticals' Long-Term Investments averaged around $3.5 billion, with its median value being $4.4 billion (2024).
  • Per our database at Business Quant, Vertex Pharmaceuticals' Long-Term Investments soared by 212620.32% in 2023 and then skyrocketed by 1769.07% in 2025.
  • Quarter analysis of 4 years shows Vertex Pharmaceuticals' Long-Term Investments stood at $112.2 million in 2022, then skyrocketed by 2126.2% to $2.5 billion in 2023, then skyrocketed by 104.5% to $5.1 billion in 2024, then increased by 12.04% to $5.7 billion in 2025.
  • Its last three reported values are $5.7 billion in Q3 2025, $5.6 billion for Q2 2025, and $5.2 billion during Q1 2025.